Cargando…
SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis
INTRODUCTION: Pheochromocytomas and paragangliomas (PCC/PGL) are rare neuroendocrine tumors and can secrete catecholamine. Previous studies have found that SDHB immunohistochemistry (IHC) can predict SDHB germline gene mutation, and SDHB mutation is closely associated with tumor progression and meta...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061060/ https://www.ncbi.nlm.nih.gov/pubmed/37008946 http://dx.doi.org/10.3389/fendo.2023.1121397 |
_version_ | 1785017215811059712 |
---|---|
author | Su, Tingwei Yang, Yifan Jiang, Lei Xie, Jing Zhong, Xu Wu, Luming Jiang, Yiran Zhang, Cui Zhou, Weiwei Ye, Lei Ning, Guang Wang, Weiqing |
author_facet | Su, Tingwei Yang, Yifan Jiang, Lei Xie, Jing Zhong, Xu Wu, Luming Jiang, Yiran Zhang, Cui Zhou, Weiwei Ye, Lei Ning, Guang Wang, Weiqing |
author_sort | Su, Tingwei |
collection | PubMed |
description | INTRODUCTION: Pheochromocytomas and paragangliomas (PCC/PGL) are rare neuroendocrine tumors and can secrete catecholamine. Previous studies have found that SDHB immunohistochemistry (IHC) can predict SDHB germline gene mutation, and SDHB mutation is closely associated with tumor progression and metastasis. This study aimed to clarify the potential effect of SDHB IHC as a predictive marker for tumor progression in PCC/PGL patients. METHODS: We included PCC/PGL patients diagnosed in Ruijin Hospital, Shanghai Jiao Tong University School of Medicine from 2002 to 2014 for retrospective analysis and discovered that SDHB (-) staining patients had poorer prognoses. Then we examined SDHB protein expression by IHC on all tumors in the prospective series, which was composed of patients from 2015 to 2020 in our center. RESULTS: In the retrospective series, the median follow-up was 167 months, and during follow-up, 14.4% (38/264) patients developed metastasis or recurrence, and 8.0% (22/274) patients died. Retrospective analysis revealed that 66.7% (6/9) of participants in the SDHB (-) group and 15.7% (40/255) of those in the SDHB (+) group developed progressive tumors (OR: 10.75, 95% CI: 2.72-52.60, P=0.001), and SDHB (-) was independently associated with poor outcomes after adjusting by other clinicopathological parameters (OR: 11.68, 95% CI: 2.58-64.45, P=0.002). SDHB (-) patients had shorter disease-free survival (DFS) and overall survival (OS) (P<0.001) and SDHB (-) was significantly associated with shorter median DFS (HR: 6.89, 95% CI: 2.41-19.70, P<0.001) in multivariate cox proportional hazard analysis. In the prospective series, the median follow-up was 28 months, 4.7% (10/213) patients developed metastasis or recurrence, and 0.5% (1/217) patient died. For the prospective analysis, 18.8% (3/16) of participants in the SDHB (-) group had progressive tumors compared with 3.6% (7/197) in the SDHB (+) group (RR: 5.28, 95% CI: 1.51-18.47, P=0.009), statistical significance remained (RR: 3.35, 95% CI: 1.20-9.38, P=0.021) after adjusting for other clinicopathological factors. CONCLUSIONS: Our findings demonstrated patients with SDHB (-) tumors had a higher possibility of poor outcomes, and SDHB IHC can be regarded as an independent biomarker of prognosis in PCC/PGL. |
format | Online Article Text |
id | pubmed-10061060 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100610602023-03-31 SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis Su, Tingwei Yang, Yifan Jiang, Lei Xie, Jing Zhong, Xu Wu, Luming Jiang, Yiran Zhang, Cui Zhou, Weiwei Ye, Lei Ning, Guang Wang, Weiqing Front Endocrinol (Lausanne) Endocrinology INTRODUCTION: Pheochromocytomas and paragangliomas (PCC/PGL) are rare neuroendocrine tumors and can secrete catecholamine. Previous studies have found that SDHB immunohistochemistry (IHC) can predict SDHB germline gene mutation, and SDHB mutation is closely associated with tumor progression and metastasis. This study aimed to clarify the potential effect of SDHB IHC as a predictive marker for tumor progression in PCC/PGL patients. METHODS: We included PCC/PGL patients diagnosed in Ruijin Hospital, Shanghai Jiao Tong University School of Medicine from 2002 to 2014 for retrospective analysis and discovered that SDHB (-) staining patients had poorer prognoses. Then we examined SDHB protein expression by IHC on all tumors in the prospective series, which was composed of patients from 2015 to 2020 in our center. RESULTS: In the retrospective series, the median follow-up was 167 months, and during follow-up, 14.4% (38/264) patients developed metastasis or recurrence, and 8.0% (22/274) patients died. Retrospective analysis revealed that 66.7% (6/9) of participants in the SDHB (-) group and 15.7% (40/255) of those in the SDHB (+) group developed progressive tumors (OR: 10.75, 95% CI: 2.72-52.60, P=0.001), and SDHB (-) was independently associated with poor outcomes after adjusting by other clinicopathological parameters (OR: 11.68, 95% CI: 2.58-64.45, P=0.002). SDHB (-) patients had shorter disease-free survival (DFS) and overall survival (OS) (P<0.001) and SDHB (-) was significantly associated with shorter median DFS (HR: 6.89, 95% CI: 2.41-19.70, P<0.001) in multivariate cox proportional hazard analysis. In the prospective series, the median follow-up was 28 months, 4.7% (10/213) patients developed metastasis or recurrence, and 0.5% (1/217) patient died. For the prospective analysis, 18.8% (3/16) of participants in the SDHB (-) group had progressive tumors compared with 3.6% (7/197) in the SDHB (+) group (RR: 5.28, 95% CI: 1.51-18.47, P=0.009), statistical significance remained (RR: 3.35, 95% CI: 1.20-9.38, P=0.021) after adjusting for other clinicopathological factors. CONCLUSIONS: Our findings demonstrated patients with SDHB (-) tumors had a higher possibility of poor outcomes, and SDHB IHC can be regarded as an independent biomarker of prognosis in PCC/PGL. Frontiers Media S.A. 2023-03-16 /pmc/articles/PMC10061060/ /pubmed/37008946 http://dx.doi.org/10.3389/fendo.2023.1121397 Text en Copyright © 2023 Su, Yang, Jiang, Xie, Zhong, Wu, Jiang, Zhang, Zhou, Ye, Ning and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Su, Tingwei Yang, Yifan Jiang, Lei Xie, Jing Zhong, Xu Wu, Luming Jiang, Yiran Zhang, Cui Zhou, Weiwei Ye, Lei Ning, Guang Wang, Weiqing SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis |
title | SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis |
title_full | SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis |
title_fullStr | SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis |
title_full_unstemmed | SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis |
title_short | SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis |
title_sort | sdhb immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: a retrospective and prospective analysis |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061060/ https://www.ncbi.nlm.nih.gov/pubmed/37008946 http://dx.doi.org/10.3389/fendo.2023.1121397 |
work_keys_str_mv | AT sutingwei sdhbimmunohistochemistryforprognosisofpheochromocytomaandparagangliomaaretrospectiveandprospectiveanalysis AT yangyifan sdhbimmunohistochemistryforprognosisofpheochromocytomaandparagangliomaaretrospectiveandprospectiveanalysis AT jianglei sdhbimmunohistochemistryforprognosisofpheochromocytomaandparagangliomaaretrospectiveandprospectiveanalysis AT xiejing sdhbimmunohistochemistryforprognosisofpheochromocytomaandparagangliomaaretrospectiveandprospectiveanalysis AT zhongxu sdhbimmunohistochemistryforprognosisofpheochromocytomaandparagangliomaaretrospectiveandprospectiveanalysis AT wuluming sdhbimmunohistochemistryforprognosisofpheochromocytomaandparagangliomaaretrospectiveandprospectiveanalysis AT jiangyiran sdhbimmunohistochemistryforprognosisofpheochromocytomaandparagangliomaaretrospectiveandprospectiveanalysis AT zhangcui sdhbimmunohistochemistryforprognosisofpheochromocytomaandparagangliomaaretrospectiveandprospectiveanalysis AT zhouweiwei sdhbimmunohistochemistryforprognosisofpheochromocytomaandparagangliomaaretrospectiveandprospectiveanalysis AT yelei sdhbimmunohistochemistryforprognosisofpheochromocytomaandparagangliomaaretrospectiveandprospectiveanalysis AT ningguang sdhbimmunohistochemistryforprognosisofpheochromocytomaandparagangliomaaretrospectiveandprospectiveanalysis AT wangweiqing sdhbimmunohistochemistryforprognosisofpheochromocytomaandparagangliomaaretrospectiveandprospectiveanalysis |